Trial intelligence / Profile preview

GSK159797 dose-ranging crossover study in persistent asthma

2005-005329-68Phase 2Completed

Sponsor
GSK
Start
Feb 2006
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
Countries
1
01

Overview

Phase 2, randomised, double-blind trial of milveterol in asthma (4 arms), sponsored by GSK. Primary endpoint: Mean change from baseline in clinic visit trough FEV1 after 14 days repeat dosing. Started Feb 2006; status: completed.

02

Drugs

milveterol
03

Conditions

asthma

Beyond the preview

Go deeper on 2005-005329-68.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2005-005329-68.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call